Get all premium features to the best stock analysis tool

ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript

Here is how ADC Therapeutics SA (ADCT) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.

ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.29 per share a year ago.

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively  Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent operational updates.

LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT to report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates.

LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 135,000 of the Company's common shares to three new employees on March 2, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.